Show simple item record

dc.contributor.authorAzcue González, Naiara
dc.contributor.authorGómez Esteban, Juan Carlos
dc.contributor.authorAcera Gil, María Ángeles
dc.contributor.authorTijero Merino, Beatriz
dc.contributor.authorFernández Valle, Tamara
dc.contributor.authorAyo Mentxakatorre, Naia
dc.contributor.authorPérez Concha, Tomás
dc.contributor.authorMurueta-Goyena Larrañaga, Ane
dc.contributor.authorLafuente Sánchez, José Vicente ORCID
dc.contributor.authorPrada, Alvaro
dc.contributor.authorLópez de Munain Arregui, Adolfo José
dc.contributor.authorRuiz Irastorza, Guillermo
dc.contributor.authorRibacoba, Laureano
dc.contributor.authorGabilondo Cuellar, Iñigo
dc.contributor.authorDel Pino Sáez, Rocío
dc.date.accessioned2023-01-25T17:17:14Z
dc.date.available2023-01-25T17:17:14Z
dc.date.issued2022-12
dc.identifier.citationJournal of Translational Medicine 20 : (2022) // Article ID 569es_ES
dc.identifier.issn1479-5876
dc.identifier.urihttp://hdl.handle.net/10810/59483
dc.description.abstractBackground: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is characterized by persistent physical and mental fatigue. The post-COVID-19 condition patients refer physical fatigue and cognitive impairment sequelae. Given the similarity between both conditions, could it be the same pathology with a different precipitating factor? Objective: To describe the cognitive impairment, neuropsychiatric symptoms, and general symptomatology in both groups, to find out if it is the same pathology. As well as verify if the affectation of smell is related to cognitive deterioration in patients with post-COVID-19 condition. Methods: The sample included 42 ME/CFS and 73 post-COVID-19 condition patients. Fatigue, sleep quality, anxiety and depressive symptoms, the frequency and severity of different symptoms, olfactory function and a wide range of cognitive domains were evaluated. Results: Both syndromes are characterized by excessive physical fatigue, sleep problems and myalgia. Sustained attention and processing speed were impaired in 83.3% and 52.4% of ME/CFS patients while in post-COVID-19 condition were impaired in 56.2% and 41.4% of patients, respectively. Statistically significant differences were found in sustained attention and visuospatial ability, being the ME/CFS group who presented the worst performance. Physical problems and mood issues were the main variables correlating with cognitive performance in post-COVID-19 patients, while in ME/CFS it was anxiety symptoms and physical fatigue. Conclusions: The symptomatology and cognitive patterns were similar in both groups, with greater impairment in ME/CFS. This disease is characterized by greater physical and neuropsychiatric problems compared to post-COVID-19 condition. Likewise, we also propose the relevance of prolonged hyposmia as a possible marker of cognitive deterioration in patients with post-COVID-19.es_ES
dc.description.sponsorshipThis study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI20/01076 and co-funded by the European Union, EITB maratoia (BIOS21/COV/006) and grants for health research projects from the Basque Government (2021111006). Azcue, N. received a pre-doctoral research grant from the basque government (PRE_2021_1_0186).es_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectbrain foges_ES
dc.subjectcognitiones_ES
dc.subjecthyposmiaes_ES
dc.subjectmyalgic encephalomyelitis/chronic fatigue syndromees_ES
dc.subjectneuropsychological impairmentes_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectpost-COVID-19 conditiones_ES
dc.titleBrain fog of post-COVID-19 condition and Chronic Fatigue Syndrome, same medical disorder?es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03764-2es_ES
dc.identifier.doi10.1186/s12967-022-03764-2
dc.departamentoesNeurocienciases_ES
dc.departamentoeuNeurozientziakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco
mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Except where otherwise noted, this item's license is described as © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.